Adenosine vs Diltiazem for Treatment of SVT in the ED

Launched by ANNE E. ZEPESKI · May 19, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating two different medications, adenosine and diltiazem, to see how they affect patients with a condition called supraventricular tachycardia (SVT) while they are in the emergency department. SVT is a type of fast heart rhythm that can cause symptoms like dizziness or a racing heart. The main goal of the study is to understand how patients feel about these two treatments.

To participate in this trial, you need to be an adult aged 18 or older who has been diagnosed with acute, stable SVT while in the emergency department. However, there are some reasons you might not be eligible, such as having received certain heart medications before joining the study or having specific medical conditions like Wolff-Parkinson-White syndrome or severe lung disease. If you qualify and decide to participate, you will help researchers learn more about how these medications work and how patients experience their effects.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Adult patients (18 years and older)
• • 2. Diagnosis of acute, stable SVT in the emergency department
• Exclusion Criteria:
• • 1. Receipt of IV AV-nodal blocking agents prior to study enrollment (includes adenosine, non-dihydropyridine calcium channel blockers, beta-antagonists in pre-hospital and/or hospital setting).
• • 2. Reported or confirmed personal history of Wolff-Parkinson-White (WPW) syndrome
• • 3. History of heart failure with reduce ejection fraction (HFrEF) (LVEF\</= 40%)
• • 4. Severe bronchoconstrictive lung disease
• • 5. Prior hypersensitivity to study medication
• • 6. Previously enrolled in pilot study
• • 7. Pregnant
• • 8. Incarcerated